Angiotensin Converting Enzyme 2 News and Research

RSS

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Candidate monoclonal antibody shows hope as COVID-19 treatment

Researchers in the United States have described the effectiveness of a candidate monoclonal antibody currently being evaluated in a Phase 1 trial as a therapy for coronavirus disease 2019 (COVID-19) and its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

16 Sep 2020

New images capture startlingly high SARS-CoV-2 viral loads

Now, a team of scientists from the University of North Carolina at Chapel Hill School of Medicine produced striking images in respiratory tract cultures of the infectious form of the SARS-CoV-2 produced by infected epithelial cells.

16 Sep 2020

Sex and gender not receiving enough attention in COVID-19 trials

Researchers in Denmark and the Netherlands have conducted a study showing that sex and gender are not being adequately considered in clinical trials investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the coronavirus disease 2019 (COVID-19) pandemic.

15 Sep 2020

New antibody assay for COVID-19 promises sensitive mass-scale detection

A new paper by researchers at McMaster University and Hamilton Health Sciences, published on the preprint server medRxiv in September 2020, reports on the development of a serologic assay that is suitable for sensitive high-throughput antibody testing for COVID-19.

15 Sep 2020

Immunologists analyze types of immune response to predict an effective COVID-19 vaccine

Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

15 Sep 2020

Computational models screen for coronaviruses likely to infect humans

The researchers from Rochester Institute of Technology and the Hauptmann-Woodward Medical Research Institute produced models of the receptor-binding domain (RBD) found on outbreak strains of betacoronaviruses and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2).

14 Sep 2020

Single-molecule imaging of SARS-CoV-2 spikes on virus particles

Using single-molecule FRET analysis, a team of researchers has revealed how the different conformations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein are interconnected. Figuring out the different conformations in real-time and which conformations antibodies prefer may help design effective vaccines and drugs. The research is published on the preprint server bioRxiv*.

14 Sep 2020

A map of SARS-CoV-2 escape mutations enables the development of therapeutic antibody cocktails

A recent tour-de-force study by the US researchers describes a comprehensive approach to completely map mutations to the SARS-CoV-2 receptor-binding domain (RBD) that escape antibody binding – enabling, in turn, rational design of antibody therapeutics and appraisal of the antigenic consequences of viral evolution. The results are currently available in a bioRxiv preprint paper.

13 Sep 2020

Study sheds light on the disproportionate impact of COVID-19 on Blacks

In a study published in JAMA today, Mount Sinai researchers report findings that shed some light on the disproportionate impact of COVID-19 on Blacks, who have experienced rates of infection and death that are much greater, in some areas twice and three times more, than their proportion of the population.

11 Sep 2020

Researchers explore IgA response to SARS-CoV-2

A new study published on the preprint server bioRxiv* and conducted by researchers from The Rockefeller University in New York examined the role of IgA antibodies in preventing SARS-CoV-2 infection. In this study, the team analyzed the IgA response to SARS-CoV-2 infection in 149 individuals.

10 Sep 2020

Researchers say Influenza may increase risk of COVID-19

A recent study by researchers suggests that the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is influenced by influenza virus infection during the initial period of coronavirus disease 2019 (COVID-19) pandemic in Europe. The study is currently available on the medRxiv preprint server.

10 Sep 2020

Scientists explain how SARS-CoV-2 attacks the brain

Now, a team of scientists at Yale University revealed the changes that happen in the brain caused by SARS-CoV-2, the virus that has caused over 27.86 million people and claimed over 903,000 lives.

10 Sep 2020

Brain inflammation seen in fatal COVID-19 cases

Now, a new study by researchers at the Barts Health NHS Trust and the University of Cambridge in the United Kingdom shows that some patients develop neurological complications tied to COVID-19.

9 Sep 2020

Susceptibility to SARS-CoV-2 infection varies across bat species

A recent study by researchers at Wuhan University, China, reveals that many bat species are not potential carriers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of genetic mutations in angiotensin-converting enzyme 2 (ACE2) that prevent the entry of viruses inside bat cells. The study is currently available on the bioRxiv* preprint server.

9 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020

Host gene editing main driving force of SARS-CoV-2 mutations

A new study published on the aRxiv preprint server in September 2020 shows that the host immune response, mediated by two RNA editors, causes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to adapt and change strain characteristics.

9 Sep 2020

Limited gut inflammation in COVID-19

A new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in September 2020 shows that gut infection with this virus produces primarily mucosal immunity but also a limited inflammatory response.

8 Sep 2020

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

Early in the pandemic, scientists uncovered the role of the ACE2 receptor in SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the angiotensin-converting enzyme 2 (ACE2) receptors act as a lock and key for cell infection.

7 Sep 2020

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.

7 Sep 2020